Propantheline
Pro-banthine (propantheline) is a small molecule pharmaceutical. Propantheline was first approved as Pro-banthine on 1982-01-01. It is used to treat irritable bowel syndrome, pancreatitis, peptic ulcer, spasm, and urethral diseases amongst others in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, and muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Propantheline bromide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRO-BANTHINE | G.D. Searle | N-008843 DISCN | 1982-01-01 | 1 products |
| PRO-BANTHINE | Shire | N-008732 DISCN | 1982-01-01 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A03: Drugs for functional gastrointestinal disorders
— A03A: Drugs for functional gastrointestinal disorders
— A03AB: Synthetic anticholinergics, quaternary ammonium compounds for functional gastrointestinal disorders
— A03AB05: Propantheline
— A03C: Antispasmodics in combination with psycholeptics
— A03CA: Synthetic anticholinergic agents in combination with psycholeptics
— A03CA34: Propantheline and psycholeptics
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urolithiasis | D052878 | — | N20-N23 | — | — | — | 1 | — | 1 |
| Urinary calculi | D014545 | — | — | — | — | — | 1 | — | 1 |
| Calculi | D002137 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Propantheline |
| INN | propantheline bromide |
| Description | Propantheline bromide (INN) is an antimuscarinic agent used for the treatment of excessive sweating (hyperhidrosis), cramps or spasms of the stomach, intestines (gut) or bladder, and involuntary urination (enuresis). It can also be used to control the symptoms of irritable bowel syndrome and similar conditions. This agent can also be used for patients who experience intense GI symptoms while tapering off of TCAs.
|
| Classification | Small molecule |
| Drug class | Antimuscarinic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)[N+](C)(CCOC(=O)C1c2ccccc2Oc2ccccc21)C(C)C |
Identifiers
| PDB | — |
| CAS-ID | 298-50-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1180725 |
| ChEBI ID | 8481 |
| PubChem CID | 9279 |
| DrugBank | DB00782 |
| UNII ID | UX9Z118X9F (ChemIDplus, GSRS) |
Target
Agency Approved
CHRM2
CHRM2
CHRM1
CHRM1
CHRM3
CHRM3
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Propantheline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,189 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
69 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use